Pi-Lin Sung
Research Subjects
Pi-Lin Sung has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Tsang-Hsien Wu
The Ph.D. Program of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
1 shared publication - Chi-Ying Frederick Huang
Institute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei 11211, Taiwan
1 shared publication - Jun-Hung Lin
Taipei Veterans General Hospital
1 shared publication - Kuo-Chang Wen
Department of Obstetrics and Gynecology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan
1 shared publication - Mong-Hong Lee
Guangdong Provincial Key laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication - Peng-Hui Wang
Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
1 shared publication
Latest Publications
- Open Access
- 18 September 2019
- Published by Springer Nature in Research Square
Synergistic therapeutic effects of metformin at a clinically relevant dosage in combination with chemotherapy via the AKT/mTOR pathway on ovarian cancer
Background Ovarian cancer is the leading cause of cancer-related death among women. Metformin has antitumor effects in many cancer models. However, many studies have shown that metformin has cytotoxic activity at higher concentrations than those used for diabetic patients; this effect may be derived from high concentrations directly inducing the death of tumor cells. The synergism of metformin at clinically relevant dosages and chemotherapy in ovarian cancer remains unclear.Methods We applied two clinical databases to survey metformin use and ovarian cancer survival rate. The Cancer Genome Atlas dataset, an L1000 microarray with Gene Set Enrichment Analysis (GSEA) analysis, western blot analysis and an animal model were used to study the activity of the AKT/mTOR pathway in response to the synergistic effects of metformin and chemotherapy.Results We found that ovarian cancer patients treated with metformin had significantly longer overall survival than did patients treated without metformin. The gene profile induced by metformin in ovarian cancer predominantly involved the AKT/mTOR pathway. Micromolar concentrations of metformin alone and in combination with chemotherapy also reduced cell viability via the AKT/mTOR pathway in vitro and in vivo . Both neoadjuvant and concurrent therapy protocols showed good synergistic effects.Conclusions This study shows that metformin at clinically relevant dosages is efficacious in treating ovarian cancer, and the results can be used to guide clinical trials.
- 18 September 2019
- Published by Springer Nature in Research Square
Open AccessSynergistic therapeutic effects of metformin at a clinically relevant dosage in combination with chemotherapy via the AKT/mTOR pathway on ovarian cancer
Background Ovarian cancer is the leading cause of cancer-related death among women. Metformin has antitumor effects in many cancer models. However, many studies have shown that metformin has cytotoxic activity at higher concentrations than those used for diabetic patients; this effect may be derived from high concentrations directly inducing the death of tumor cells. The synergism of metformin at clinically relevant dosages and chemotherapy in ovarian cancer remains unclear.Methods We applied two clinical databases to survey metformin use and ovarian cancer survival rate. The Cancer Genome Atlas dataset, an L1000 microarray with Gene Set Enrichment Analysis (GSEA) analysis, western blot analysis and an animal model were used to study the activity of the AKT/mTOR pathway in response to the synergistic effects of metformin and chemotherapy.Results We found that ovarian cancer patients treated with metformin had significantly longer overall survival than did patients treated without metformin. The gene profile induced by metformin in ovarian cancer predominantly involved the AKT/mTOR pathway. Micromolar concentrations of metformin alone and in combination with chemotherapy also reduced cell viability via the AKT/mTOR pathway in vitro and in vivo . Both neoadjuvant and concurrent therapy protocols showed good synergistic effects.Conclusions This study shows that metformin at clinically relevant dosages is efficacious in treating ovarian cancer, and the results can be used to guide clinical trials.